AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10613427 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 10
Study 7732330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily) + Ranitidine (150 mg twice daily)
Number of subjects: 197
Study 7732330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride (20 mg twice daily)
Number of subjects: 197
Study 7732330 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine (150 mg twice daily)
Number of subjects: 197
Study 2258379 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 241
Study 2258379 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline (50-150 mg/day)
Number of subjects: 241
Study 6991103 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy with moderate doses of methotrexate and L-asparaginase added to standard doses of 5-fluorouracil, Adriamycin, and cyclophosphamide, along with Corynebacterium parvum or Pseudomonas vaccine.
Number of subjects: 0
Study 6991103 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudomonas vaccine
Number of subjects: 0
Study 31849201 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg intervention (one egg per day for 6 months during early complementary feeding)
Number of subjects: 135
Study 31849201 — intervention group
Group type: EXPERIMENTAL
Intervention: Egg intervention group
Number of subjects: 135
Study 31849201 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 135
Study 31849201 — intervention group
Group type: EXPERIMENTAL
Intervention: Current dietary egg intake
Number of subjects: 135
Study 31690285 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach (Group M)
Number of subjects: 262
Study 31690285 — intervention group
Group type: COMPARATOR
Intervention: Right approach (Group R)
Number of subjects: 262
Study 31690285 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 262
Study 28403798 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobicistat-boosted darunavir (800 mg) with 2 N(t)RTIs, once daily for 48 weeks
Number of subjects: 313
Study 26022901 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-bore pleural catheter (8 Fr) with manual aspiration
Number of subjects: 49
Study 26022901 — intervention group
Group type: COMPARATOR
Intervention: Standard chest tube drainage (20-24 Fr)
Number of subjects: 49
Study 23669567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin 10 mg
Number of subjects: 20
Study 23669567 — intervention group
Group type: COMPARATOR
Intervention: Oral oxybutynin 5 mg
Number of subjects: 20
Study 23669567 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical oxybutynin (7 doses of 10 mg)
Number of subjects: 20
Study 21093925 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 45
Study 21093925 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 45
Study 19235072 — intervention group
Group type: EXPERIMENTAL
Intervention: Social-cognitive theories (e.g. Transtheoretical model, Theory of Planned Behaviour, Protection Motivation Theory, Social Cognitive Theory)
Number of subjects: 1183
Study 15741734 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril (ACE inhibitor)
Number of subjects: 57
Study 15741734 — intervention group
Group type: COMPARATOR
Intervention: Losartan (ARB)
Number of subjects: 57
Study 12433761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound screening for abdominal aortic aneurysms
Number of subjects: 67800
Study 12433761 — intervention group
Group type: COMPARATOR
Intervention: Control group (not offered screening)
Number of subjects: 67800
Study 10490297 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol + UVB
Number of subjects: 178
Study 10490297 — intervention group
Group type: COMPARATOR
Intervention: Vehicle + UVB
Number of subjects: 178
Study 10490297 — intervention group
Group type: COMPARATOR
Intervention: Calcipotriol alone
Number of subjects: 178
Study 8944120 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopamidol 370 mg l/l
Number of subjects: 100
Study 8944120 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate 350 mg l/l
Number of subjects: 100
Study 8944120 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol 300 mg l/l
Number of subjects: 100
Study 8944120 — intervention group
Group type: COMPARATOR
Intervention: Ioxaglate 320 mg l/l
Number of subjects: 100
Study 1720488 — intervention group
Group type: EXPERIMENTAL
Intervention: Isradipine at 1.25‐2.5 mg twice daily
Number of subjects: 28
Study 1720488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 6749440 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulconazole nitrate 1.0 percent cream
Number of subjects: 96
Study 6749440 — intervention group
Group type: COMPARATOR
Intervention: Miconazole nitrate 2.0 percent cream
Number of subjects: 96
Study 31850996 — intervention group
Group type: COMPARATOR
Intervention: Standard intravenous fluid regimen (S-group)
Number of subjects: 135
Study 31850996 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive intravenous fluid regimen (R-group)
Number of subjects: 135
Study 31850996 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NT-Pro-BNP
Number of subjects: 135
Study 31850996 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid volumes
Number of subjects: 135
Study 31850996 — intervention group
Group type: COMPARATOR
Intervention: CPC vs no-CPC
Number of subjects: 135
Study 31141394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade®); 805 ml fluid intake, 6.5 MJ energy intake, 187 g carbohydrate intake; p=0.002 for energy, p<0.001 for carbohydrate
Number of subjects: 132
Study 31141394 — intervention group
Group type: COMPARATOR
Intervention: Water; 751 ml fluid intake, 5.7 MJ energy intake, 151 g carbohydrate intake
Number of subjects: 132
Study 31141394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade®); 1,047 ml acute fluid intake, 3,337 ml total fluid intake at end of trial days; p=0.004 for acute fluid intake, p<0.01 for total fluid intake
Number of subjects: 132
Study 31141394 — intervention group
Group type: COMPARATOR
Intervention: Low-alcohol beer (Hahn Ultra®); 850 ml acute fluid intake, 2,982 ml total fluid intake at end of trial days
Number of subjects: 132
Study 31141394 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drink (Gatorade®); urine specific gravity 1.021
Number of subjects: 132
Study 31141394 — intervention group
Group type: COMPARATOR
Intervention: Low-alcohol beer (Hahn Ultra®); urine specific gravity 1.016
Number of subjects: 132
Study 28454674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/3 IPV‐Al
Number of subjects: 824
Study 28454674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/5 IPV‐Al
Number of subjects: 824
Study 28454674 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10 IPV‐Al
Number of subjects: 824
Study 28454674 — intervention group
Group type: COMPARATOR
Intervention: IPV
Number of subjects: 824
Study 25867599 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzyme-Modified Ginseng Extract (EG) cream
Number of subjects: 23
Study 25867599 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 22589421 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 118
Study 22589421 — intervention group
Group type: COMPARATOR
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 118
Study 22688223 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention and feedback tool for GPs, including a two-hour feedback session and training to generate eligible patient lists from EMR.
Number of subjects: 30000
Study 22688223 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 30000
Study 22688223 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention and feedback tool for GPs.
Number of subjects: 30000
Study 19126049 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin treatment group
Number of subjects: 78
Study 19126049 — intervention group
Group type: COMPARATOR
Intervention: Topical treatment group
Number of subjects: 78
Study 17823421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoovovegetarian diet (LOV-D)
Number of subjects: 176
Study 17823421 — intervention group
Group type: COMPARATOR
Intervention: Standard calorie-restricted, low-fat omnivorous diet (STD-D)
Number of subjects: 176
Study 17823421 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference-No groups
Number of subjects: 176
Study 17823421 — intervention group
Group type: EXPERIMENTAL
Intervention: Both diets (LOV-D and STD-D)
Number of subjects: 176
Study 16389910 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment allocation
Number of subjects: 0
Study 16389910 — intervention group
Group type: COMPARATOR
Intervention: Control group allocation
Number of subjects: 0
Study 12407487 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based melaleuca oral solution, administered four times daily for 2-4 weeks
Number of subjects: 27
Study 12407487 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free melaleuca oral solution, administered four times daily for 2-4 weeks
Number of subjects: 27
Study 10509988 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin
Number of subjects: 150
Study 10509988 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aprotinin
Number of subjects: 150
Study 10509988 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 8748337 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetic cream, EMLA
Number of subjects: 54
Study 8748337 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment (Vaseline)
Number of subjects: 54
Study 1955605 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Inoculation Training (SIT)
Number of subjects: 45
Study 1955605 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE)
Number of subjects: 45
Study 1955605 — intervention group
Group type: COMPARATOR
Intervention: Supportive Counseling (SC)
Number of subjects: 45
Study 1955605 — intervention group
Group type: COMPARATOR
Intervention: Wait-list Control (WL)
Number of subjects: 45
Study 6754634 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (300 mg)
Number of subjects: 6
Study 6754634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 6754634 — intervention group
Group type: COMPARATOR
Intervention: Non-treatment (control)
Number of subjects: 6
Study 30954936 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous peripheral nerve stimulation (PNS)
Number of subjects: 28
Study 30954936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 28992513 — intervention group
Group type: EXPERIMENTAL
Intervention: Second Step Child Protection Unit videos
Number of subjects: 438
Study 28992513 — intervention group
Group type: COMPARATOR
Intervention: Control group (watching videos on child obesity)
Number of subjects: 438
Study 27321490 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT
Number of subjects: 32
Study 27321490 — intervention group
Group type: COMPARATOR
Intervention: ADM
Number of subjects: 32
Study 27321490 — intervention group
Group type: EXPERIMENTAL
Intervention: NPWT + ADM
Number of subjects: 32
Study 25147070 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA 1g
Number of subjects: 44
Study 25147070 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA 2g
Number of subjects: 44
Study 25147070 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 FA 4g
Number of subjects: 44
Study 25147070 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 20662863 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implants placed in fresh extraction sockets
Number of subjects: 35
Study 20595193 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 3 g/day
Number of subjects: 64
Study 20595193 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine (ALC) 1 g/day
Number of subjects: 64
Study 20595193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 17174460 — intervention group
Group type: EXPERIMENTAL
Intervention: Crocus sativus petal 15 mg bid (morning and evening)
Number of subjects: 40
Study 17174460 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 10 mg bid (morning and evening)
Number of subjects: 40
Study 15843959 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsiflexors' ElectroStimulation (ES) training (4 weeks, 4 s/week, 40 min/session)
Number of subjects: 21
Study 12473257 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline treatment for 3 days
Number of subjects: 50
Study 12473257 — intervention group
Group type: EXPERIMENTAL
Intervention: Perhexiline treatment
Number of subjects: 50
Study 9523406 — intervention group
Group type: EXPERIMENTAL
Intervention: Heightened self-focus
Number of subjects: 0
Study 9523406 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous forms of stereotype suppression
Number of subjects: 0
Study 7699528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 1 mg/kg
Number of subjects: 285
Study 7699528 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone 2 mg/kg
Number of subjects: 285
Study 7699528 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 285
Study 2617153 — intervention group
Group type: EXPERIMENTAL
Intervention: Bendroflumethiazide (2.5 mg o.d.)
Number of subjects: 34
Study 2617153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 910742 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivonex
Number of subjects: 0
Study 910742 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexical
Number of subjects: 0
Study 910742 — intervention group
Group type: EXPERIMENTAL
Intervention: Precision LR
Number of subjects: 0
Study 910742 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 31786114 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed pleural technique (preservation of pleural integrity)
Number of subjects: 100
Study 31786114 — intervention group
Group type: COMPARATOR
Intervention: Open pleural procedure (without preservation of pleural integrity)
Number of subjects: 100
Study 29698710 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy (1000 cm3 of CO2)
Number of subjects: 16
Study 29698710 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 16
Study 29698710 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboxytherapy
Number of subjects: 16
Study 27513714 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000IU vitamin D3/day from weeks 26-28 until childbirth
Number of subjects: 28
Study 27513714 — intervention group
Group type: COMPARATOR
Intervention: Placebo (not explicitly mentioned but implied as control)
Number of subjects: 28
Study 27513714 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000IU vitamin D3/day
Number of subjects: 28
Study 24608494 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronized intermittent mandatory ventilation
Number of subjects: 60
Study 24608494 — intervention group
Group type: COMPARATOR
Intervention: Pressure support ventilation with volume guarantee
Number of subjects: 60
Study 22911072 — intervention group
Group type: EXPERIMENTAL
Intervention: Early removal of nasogastric tube (48 hours)
Number of subjects: 150
Study 22911072 — intervention group
Group type: COMPARATOR
Intervention: Conventional nasogastric decompression for 6 to 10 days
Number of subjects: 150
Study 20631209 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-channel neuron activation during visual discrimination task
Number of subjects: 0
Study 20631209 — intervention group
Group type: COMPARATOR
Intervention: Maximally responsive sensory neurons
Number of subjects: 0
Study 18306372 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise training (RET)
Number of subjects: 242
Study 18306372 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET)
Number of subjects: 242
Study 18306372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontaxane-based therapies
Number of subjects: 242
Study 16004047 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser-induced autofluorescence (LIAF) combined with artificial neural network (ANN)
Number of subjects: 0
Study 12854296 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship-enhancing program of care (REPC)
Number of subjects: 50
Study 10506041 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous 2.2 g dose of co-amoxiclav
Number of subjects: 106
Study 10506041 — intervention group
Group type: COMPARATOR
Intervention: Identical appearing saline (control)
Number of subjects: 106
Study 8671156 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (gonadotrophin-releasing hormone agonist)
Number of subjects: 66
Study 8671156 — intervention group
Group type: COMPARATOR
Intervention: Control group (no triptorelin)
Number of subjects: 66
Study 2006616 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (100 mg/day)
Number of subjects: 18
Study 2006616 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg 3 times daily)
Number of subjects: 18
Study 2006616 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Atenolol + Nifedipine)
Number of subjects: 18
Study 2006616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6751338 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 micrograms atropine methonitrate
Number of subjects: 17
Study 6751338 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 80 micrograms atropine methonitrate and 450 micrograms reproterol
Number of subjects: 17
Study 31796028 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Health Care Package (OHCP) delivered to mothers of 1-6-year-old children
Number of subjects: 0
Study 31796028 — intervention group
Group type: COMPARATOR
Intervention: Usual care advice available at the AWCs
Number of subjects: 0
Study 30033159 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg caffeine
Number of subjects: 50
Study 30033159 — intervention group
Group type: COMPARATOR
Intervention: 0 mg/kg caffeine (placebo)
Number of subjects: 50
Study 30033159 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg caffeine
Number of subjects: 50
Study 30033159 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment overall
Number of subjects: 50
Study 30033159 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine treatment and BMI
Number of subjects: 50
Study 27236320 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 50 mg oral
Number of subjects: 14
Study 27236320 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 400 mg oral
Number of subjects: 14
Study 27236320 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 50 mg intravenous
Number of subjects: 14
Study 27236320 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole 400 mg intravenous
Number of subjects: 14
Study 27236320 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole (both doses)
Number of subjects: 14
Study 25007675 — intervention group
Group type: EXPERIMENTAL
Intervention: Local packing of Nasopore combined with hemocoagulase injection (1 U of hemocoagulase dissolved in 0.5 ml saline)
Number of subjects: 68
Study 25007675 — intervention group
Group type: COMPARATOR
Intervention: Local packing of Nasopore combined with saline injection (0.5 ml saline)
Number of subjects: 68
Study 22581209 — intervention group
Group type: EXPERIMENTAL
Intervention: Stapled ileocolonic anastomosis
Number of subjects: 84
Study 22581209 — intervention group
Group type: COMPARATOR
Intervention: Handsewn anastomosis
Number of subjects: 84
Study 20926013 — intervention group
Group type: EXPERIMENTAL
Intervention: multimodal analgesia protocol (oral celecoxib and tramadol before and after surgery; intra‐articular injection of morphine, ropivacaine, adrenaline, and betamethasone during surgery)
Number of subjects: 100
Study 20926013 — intervention group
Group type: EXPERIMENTAL
Intervention: multimodal analgesia protocol
Number of subjects: 100
Study 20926013 — intervention group
Group type: COMPARATOR
Intervention: oral and intra‐articular placebo
Number of subjects: 100
Study 18705758 — intervention group
Group type: EXPERIMENTAL
Intervention: Male circumcision
Number of subjects: 11050
Study 15653024 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol controlled release/extended release (CR/XL)
Number of subjects: 5
Study 15653024 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 12435158 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine and 5-day regimen of primaquine at 15 mg/day
Number of subjects: 1482
Study 12435158 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 1482
Study 11910651 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2.0 mg/dienogest 2.0 mg (Climodien)
Number of subjects: 0
Study 11910651 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol valerate 2.0 mg/dienogest 3.0 mg (E2Val 2/DNG 3)
Number of subjects: 0
Study 11910651 — intervention group
Group type: COMPARATOR
Intervention: Estradiol 2.0 mg/estriol 1.0 mg/norethisterone acetate 1.0 mg (Kliogest)
Number of subjects: 0
Study 9239164 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegafur
Number of subjects: 488
Study 9239164 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐FU
Number of subjects: 488
Study 9239164 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 488
Study 8478230 — intervention group
Group type: EXPERIMENTAL
Intervention: Strontium-89 (10.8 mCi single injection)
Number of subjects: 126
Study 8478230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 3762845 — intervention group
Group type: EXPERIMENTAL
Intervention: Paregoric
Number of subjects: 85
Study 3762845 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (combined loading and titration)
Number of subjects: 85
Study 3762845 — intervention group
Group type: EXPERIMENTAL
Intervention: More than one agent (including diazepam)
Number of subjects: 85
Study 3762845 — intervention group
Group type: EXPERIMENTAL
Intervention: No treatment
Number of subjects: 85
Study 30471827 — intervention group
Group type: EXPERIMENTAL
Intervention: The Bedside PEWS
Number of subjects: 16213
Study 30471827 — intervention group
Group type: COMPARATOR
Intervention: CDR PEWS
Number of subjects: 16213